A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...

The Huntington’s disease treatment market is evolving, with novel therapies targeting mHTT and reshaping the future of ...

Yes, in fact, on August 18th, 2023, the FDA approved Valbenazine, or INGREZZA, for the treatment of chorea in adults with Huntington’s disease. The FDA’s decision was based on data from the ...

Huntington’s disease is a rare and incurable hereditary ... HD, also known as Huntington’s chorea, leads to symptoms that may impact movement, behavior, and cognition. According to the Genetic ...

Too much of dopamine can cause problems.‌ The most widely recognized cause of chorea is Huntington's disease — a hereditary disorder. But, there can be many other causes, some of which are ...

Recently, Neurocrine submitted a proposal to the FDA for the use of Ingrezza (valbenazine) as a treatment for chorea associated with Huntington's disease. The decision from the FDA is expected to ...

"Huntington's disease has long been considered a disease ... as well as medical management of chorea. How functional, cognitive, and motor scores varied over time was also assessed.

The disease was formerly named Huntington's chorea because it causes abnormal involuntary movements called "chorea." The disease is caused by an abnormal copy of the huntingtin gene on chromosome ...

The current interim results from KINECT-HD2 (Sustained Improvements With Once-Daily Valbenazine in Chorea Associated With Huntington's Disease: Interim Results From a Long-Term Open-Label Study ...

uniQure noted that Huntington's disease, which results in chorea, cognitive decline, and behavioural abnormalities, affects approximately 70,000 people in Europe and the US, with many more at risk.